Does dexamethasone enhance the efficacy of alizapride in cis-platinum-induced delayed vomiting and nausea?

Oncology

Volumn 55, Issue 4, 1998, Pages 293-299

  Munstedt K ^a,c   Wunderlich, I ^a   Blauth Eckmeyer, E ^b   Zygmunt, M ^a   Vahrson, H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Synthelabo Arzneimittel GmbH   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Alizapride; Dexamethasone; Emesis, delayed; Nausea, delayed; Tropisetron; Vomiting, delayed

Indexed keywords

ALIZAPRIDE; CISPLATIN; DEXAMETHASONE; TROPISETRON;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VOMITING; WELLBEING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; PYRROLIDINES; QUESTIONNAIRES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 2642681619     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011866     Document Type: Article

References (24)

1. Hursti TJ, Fredrikson M, Steineck G, Börjeson S, Fürst CJ, Peterson C: Endogenous cortisol exerts antiementic effect similar to that of exogenous corticosteroids. Br J Cancer 1993;68: 112-114.
2. Livera P, Trojano M, Simone I: Acute changes in blood CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol 1985;231:336-339.
3. Young SN: Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: Roles of tryptophan catabolism and kynurenine synthesis. Br J Pharmacol 1981;74:695.
4. Fredrikson M, Hursti TJ, Steineck G, Fürst CJ, Börjeson S, Peterson C: Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer 1992;65:779-780.
5. Sagar S: The current role of anti-emetic drugs in oncology: A recent revolution in patients' symptom control. Cancer Treat Rev 1991;18: 95-135.
6. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S: Controlling delayed vomiting: Double blind, randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-114.
7. Clark RA, Gralla RJ: Delayed emesis: A dilemma in antiemetic control. Support Care Cancer 1993;1/4:182-185.
8. Fredrikson M, Hursti TJ, Steineck G, Fürst CJ, Börjeson S, Peterson C: Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer 1994;70:642-645.
9. Hesketh PJ: Treatment of chemotherapy-induced emesis in the 1990's: Impact of the 5-HT3 receptor antagonists. Support Care Cancer 1994;2:286-292.
10. Schlimok G, Kaiser H: Stellenwert der Corticoide in der Hämatologie/Onkologie des Erwachsenenalters. Med Klin 1995;90:579-584.
11. Scherbel G, Bodenmüller-Kroll R, Matthias M, Nielsen M, von Richthofen K-F: Antiemetische Therapieformen - Kosten und Effektivität im Vergleich. Arzneimitteltherapie 1994; 12/6(suppl 17):1-8.
12. Roila F, Tonato M, Del Favero A: Prevention of chemotherapy-induced emesis: The state of the art. Dig Dis 1993;11:343-353.
13. Peterson C, Hursti TJ, Börjeson S, Avall-Lundquist E, Fredrikson M, Fürst CJ, Lomberg H, Steineck G: Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer 1996;4:440-446.
14. Aasebo U, Slordal L: Transient reduction in serum cortisol levels after dexamethasone antiemetic therapy in cancer patients undergoing chemotherapy. Acta Oncol 1990;29:314-316.
15. Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M, Patoia L, Santi E, Penza O, Ballatori E, del Favero A: Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 1991;14/3:238-242.
16. Münstedt K, Milch W, Blauth-Eckmeyer E, Spänle A, Vahrson H, Reimer Ch: Delayed emesis and subjective well-being in cisplatinum containing chemotherapy. Onkologie 1995;18:23-26.
17. de Haes JCJM, van Knippenberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990;62:1034-1038.
18. Gridelli C, Ianniello GP, Ambrosini G, Mustacchi G, Pedicini T, Farris A, Jabobelli S, Rossi G, Boni C, D'Aprile M, DeLena M, DiCarlo A, Bonsignori M, Silingardi V, Catalano G, Mosconi M, Oliveri A, Bianco AR: Ondansetron vs ondansetron plus dexamethasone in the prophylaxis of delayed emesis over three courses of cisplatin chemotherapy: Results of a double blind randomized study (abstract). Proc Annu Meet Am Soc Clin Oncol 1996;15:545.
19. Kris MG, Pisters KMW, Hinkley L: Delayed emesis following anticancer chemotherapy. Support Care Cancer 1994;2:297-300.
20. Haid M: Steroid antiemesis may be harmful. N Engl J Med 1981;304:1237.
21. Powell CB, Mutch DG, Kao M-S, Kao JW-Y, Perry D, Westphale E, Collins JL: Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. Cancer 1990;65:446-472.
22. Aapro MS, Alberts DS: High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 1981;7:11-14.
23. Kris MG, Radford J, Pizzo B, Inabinet R, Lovelace J, Casey M, Hesketh P: Dose-ranging antiemetic trial of the NK-1 receptor antagonist CP-122,721: A new approach for acute and delayed emesis following cisplatin (abstract 1780). Proc Annu Meet Am Soc Clin Oncol 1996;15:547.
24. Malik IA, Khan WA, Quazilbash M, Ata E, Butt A, Khan MA: Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high dose of cisplatin. Am J Clin Oncol 1995;18/2: 170-175.